Cytek BioSciences Inc (NASDAQ: CTKB) open the trading on Wednesday, with great promise as it jumped 36.03% to $7.40, before settling in for the price of $5.44 at the close. Taking a more long-term approach, CTKB posted a 52-week range of $3.80-$9.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 36.02% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 8.21%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -78.72%. This publicly-traded company’s shares outstanding now amounts to $130.71 million, simultaneously with a float of $119.40 million. The organization now has a market capitalization sitting at $973.14 million. At the time of writing, stock’s 50-day Moving Average stood at $5.23, while the 200-day Moving Average is $6.19.
Cytek BioSciences Inc (CTKB) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. Cytek BioSciences Inc’s current insider ownership accounts for 9.21%, in contrast to 56.94% institutional ownership. According to the most recent insider trade that took place on Apr 19 ’24, this organization’s CHIEF TECHNOLOGY OFFICER sold 20,000 shares at the rate of 5.87, making the entire transaction reach 117,400 in total value, affecting insider ownership by 5,988,502. Preceding that transaction, on Apr 09 ’24, Company’s CHIEF TECHNOLOGY OFFICER sold 1,900 for 7.00, making the whole transaction’s value amount to 13,304. This particular insider is now the holder of 6,008,502 in total.
Cytek BioSciences Inc (CTKB) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
Cytek BioSciences Inc’s EPS decrease for this current 12-month fiscal period is -78.72% and is forecasted to reach 0.14 in the upcoming year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Let’s observe the current performance indicators for Cytek BioSciences Inc (CTKB). It’s Quick Ratio in the last reported quarter now stands at 5.47. The Stock has managed to achieve an average true range (ATR) of 0.37. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.84. Similarly, its price to free cash flow for trailing twelve months is now 88.63.
In the same vein, CTKB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.08, a figure that is expected to reach 0.07 in the next quarter, and analysts are predicting that it will be 0.14 at the market close of one year from today.
Technical Analysis of Cytek BioSciences Inc (CTKB)
[Cytek BioSciences Inc, CTKB] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 89.35% While, its Average True Range was 0.44.
Raw Stochastic average of Cytek BioSciences Inc (CTKB) in the period of the previous 100 days is set at 100.00%, which indicates a major rise in contrast to 100.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 129.13% that was higher than 75.73% volatility it exhibited in the past 100-days period.
